Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $164.00. The company’s shares closed yesterday at $55.06.

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

The company’s shares closed yesterday at $29.89. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. According to ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Following Trump's election victory, investors responded Wednesday by pouring a lot of money into exchange-traded funds. In this week's ETF Wrap, Christine Idzelis broke down the money flows and the ...